Application of nirmatrelvir/ritonavir for the treatment of severe COVID-19 in a 3-year-old child
Paxlovid can effectively inhibit the replication of SARS-CoV-2 and help in improving the clinical manifestations in pediatric COVID-19 patients. Our study provided novel information on Paxlovid treatment in very young children.
Authors
- Xia Wang (ORCID: https://orcid.org/0000-0003-2157-388X)
- E Wen (ORCID: https://orcid.org/0009-0002-2728-7243)
- Yuping Zhang (ORCID: https://orcid.org/0000-0003-1055-2071)
- Yang Wang (ORCID: https://orcid.org/0009-0000-6136-1932)
- Zhifeng Wu (ORCID: https://orcid.org/0000-0003-1119-1984)
- Jingbin Huang (ORCID: https://orcid.org/0000-0003-0702-2248)
- Shuyan Quan
Institutions
- Army Medical University (CN)
- Xinqiao Hospital (CN)
Publication Details
- Journal
- The Journal of Infection in Developing Countries
- Published
- 2024-11-30
- DOI
- https://doi.org/10.3855/jidc.18685
- Citations
- 1
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.39
Funders
- National Natural Science Foundation of China
- Army Medical University